Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

Leukemia

Volumn 15, Issue 7, 2001, Pages 1001-1010

  Tse, K F ^a   Novelli, E ^a   Civin, C I ^a   Bohmer, F D ^b   Small, D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

FLT3; Inhibitors; Leukemia; Tyrosine kinase

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; FLT3 LIGAND; GENE PRODUCT; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 3; STAT5 PROTEIN; STAT5B PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DEREGULATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSFECTION; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0034895025     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402199     Document Type: Article

References (78)

1. Hematopoietic growth factors and the regulation of differentiative decisions
2. Cytokine receptors and signal transduction
3. Cellular hematopoiesis in the twentieth century
4. Growth factor receptor tyrosine kinases
5. The protein kinase family conserved features and deduced phylogeny of the catalytic domains
6. Hematopoietic receptors of class III receptor-type tyrosine kinases
7. STK-1, the human homolog of Flk-2/FLT-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells
8. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase
9. Expression of the Flt3 receptor and its ligand on hematopoietic cells
10. low CD34+ progenitor cells isolated from human bone marrow are functionally distinct
11. Multi-level effects of Flt3 ligand on human hematopoiesis: Expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors
12. Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro
13. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors
14. Flk2/Flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors
15. Targeted disruption of the Flk2/Flt3 gene leads to deficiencies in primitive hematopoietic progenitors
16. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs
17. Effect of Flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells
18. c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
19. Receptor protein-tyrosine kinases and their signal transduction pathways
20. Dimerization of cell surface receptors in signal transduction
21. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells
22. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells
23. Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase
24. Analysis of the mitogenic pathway of the FLT3 receptor and characterization in its C terminal region of a specific binding site for the PI3 kinase
25. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates
26. Essential role of signal transducer and activator of transcription STAT5A but not STAT5B for FLT3-dependent signaling
27. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation
28. Transforming activities of human CSF-1 receptors with different point mutations at codon 301 in their extracellular domains
29. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines
30. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
31. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
32. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia
33. Fusion of PDGF receptor β to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
34. The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic meylomonocytic leukemia is a transforming protein that self-associates and activates PDGFBR kinase-dependent signaling pathways
35. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia
36. Internal tandem duplication of the Flt3 gene found in acute myeloid leukemia
37. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia
38. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children
39. Prevalence and prognostic significance of flt3 internal tandem duplication in pediatric acute myeloid leukemia
40. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia
41. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
42. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
43. FLT3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
44. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: Heterogeneity in response and synergy with other hematopoietic growth factors
45. C-fms expression in acute leukemias with complex phenotypes
46. M-CSF and M-CSF receptor gene expression in acute myelomonocytic leukemias
47. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias
48. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
49. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells
50. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines
51. The roles of stem cell self-renewal and autocrine growth factor production in the biology of myeloid leukemia
52. Interleukin-6-type cytokines in myeloproliferative disease
53. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
54. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class
55. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors
56. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: Structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins
57. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation
58. Epidermal-growth-factor-dependent activation of the src-family kinases
59. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
60. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis
61. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
62. The SH3 domain-binding T cell tyrosyl phosphoprotein p120. Demonstration of its identity with the c-cbl protooncogene product and in vivo complexes with Fyn, Grb2, and phosphatidylinositol 3-kinase
63. The protein product of the c-cbl protooncogene is the 120-kDa tyrosine-phosphorylated protein in Jurkat cells activated via the T cell antigen receptor
64. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas
65. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins
66. Expression of Flt3-ligand by the endothelial cell
67. Flt3-ligand production by human bone marrow stromal cells
68. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: Regulation of Bcl-2 and Bax
69. In vivo treatment of mutant FLT3-transformed murine leukemia with tyrosine kinase inhibitor
70. Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins
71. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells
72. Phosphorylation site-specific inhibition of platelet-derived growth factor B-receptor autophosphorylation by the receptor blocking tyrphostin AG1296
73. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
74. Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias
75. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
76. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl
77. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
78. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to AML blasts harboring FLT3/ITD mutations